CA2614232A1 - Pyrazolo [3,4-d] azepine derivatives as histamine h3 antagonists - Google Patents
Pyrazolo [3,4-d] azepine derivatives as histamine h3 antagonists Download PDFInfo
- Publication number
- CA2614232A1 CA2614232A1 CA002614232A CA2614232A CA2614232A1 CA 2614232 A1 CA2614232 A1 CA 2614232A1 CA 002614232 A CA002614232 A CA 002614232A CA 2614232 A CA2614232 A CA 2614232A CA 2614232 A1 CA2614232 A1 CA 2614232A1
- Authority
- CA
- Canada
- Prior art keywords
- methanol
- mixture
- aryl
- heteroaryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title description 2
- RMUDBHOUKWNOLH-UHFFFAOYSA-N pyrazolo[3,4-d]azepine Chemical class C1=CN=CC=C2C=NN=C21 RMUDBHOUKWNOLH-UHFFFAOYSA-N 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 102
- 230000008569 process Effects 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 9
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 210
- -1 hydroxy, cyano, amino Chemical group 0.000 claims description 107
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 125000000623 heterocyclic group Chemical group 0.000 claims description 47
- 125000001424 substituent group Chemical group 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 125000005418 aryl aryl group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 284
- 239000005557 antagonist Substances 0.000 abstract description 10
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 208000020016 psychiatric disease Diseases 0.000 abstract description 3
- 150000003217 pyrazoles Chemical class 0.000 abstract description 3
- 230000000926 neurological effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 777
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 450
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 226
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 159
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 134
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 125
- 239000000243 solution Substances 0.000 description 109
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 108
- 229910021529 ammonia Inorganic materials 0.000 description 106
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 96
- 238000012799 strong cation exchange Methods 0.000 description 83
- 239000002904 solvent Substances 0.000 description 77
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 72
- 229910052786 argon Inorganic materials 0.000 description 67
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 62
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 57
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 53
- 238000003756 stirring Methods 0.000 description 46
- 238000010992 reflux Methods 0.000 description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 239000000047 product Substances 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- 239000000741 silica gel Substances 0.000 description 32
- 229910002027 silica gel Inorganic materials 0.000 description 32
- 238000004440 column chromatography Methods 0.000 description 31
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 31
- 235000019341 magnesium sulphate Nutrition 0.000 description 31
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 26
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 239000012043 crude product Substances 0.000 description 23
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 20
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 18
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 description 18
- PEJXGIXLNJDHNZ-UHFFFAOYSA-N 6-benzyl-4,5,7,8-tetrahydro-1h-pyrazolo[3,4-d]azepine Chemical compound C1CC2=CNN=C2CCN1CC1=CC=CC=C1 PEJXGIXLNJDHNZ-UHFFFAOYSA-N 0.000 description 17
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 239000012298 atmosphere Substances 0.000 description 16
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 15
- 229960001340 histamine Drugs 0.000 description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- KROXNGTXSOPSRS-UHFFFAOYSA-N 1-[4-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)phenyl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C(N2N=C3CCNCCC3=C2)C=C1 KROXNGTXSOPSRS-UHFFFAOYSA-N 0.000 description 14
- 239000002808 molecular sieve Substances 0.000 description 14
- 125000002950 monocyclic group Chemical group 0.000 description 14
- 235000011181 potassium carbonates Nutrition 0.000 description 14
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 239000012267 brine Substances 0.000 description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 12
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- PJISIGKHCIEAKT-UHFFFAOYSA-N tert-butyl 4,5,7,8-tetrahydro-1h-pyrazolo[3,4-d]azepine-6-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2=CNN=C21 PJISIGKHCIEAKT-UHFFFAOYSA-N 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 10
- GRBXELGNDLKUOA-UHFFFAOYSA-N tert-butyl 2-(4-bromophenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C1=CC=C(Br)C=C1 GRBXELGNDLKUOA-UHFFFAOYSA-N 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- ZKSLBQITPNATCT-UHFFFAOYSA-N 1,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepine Chemical compound C1CNCCC2=C1NN=C2 ZKSLBQITPNATCT-UHFFFAOYSA-N 0.000 description 8
- BZQUQLBDAKYDCX-UHFFFAOYSA-N 1-[4-(6-benzyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C(N2N=C3CCN(CC=4C=CC=CC=4)CCC3=C2)C=C1 BZQUQLBDAKYDCX-UHFFFAOYSA-N 0.000 description 8
- TVUIYWDZNFGFTC-UHFFFAOYSA-N 1-benzyl-5-chloro-2,3,6,7-tetrahydroazepine-4-carbaldehyde Chemical compound C1CC(Cl)=C(C=O)CCN1CC1=CC=CC=C1 TVUIYWDZNFGFTC-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- FYDZIWMYRVUMCV-UHFFFAOYSA-N 1-[5-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)pyridin-2-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C(N2N=C3CCNCCC3=C2)C=N1 FYDZIWMYRVUMCV-UHFFFAOYSA-N 0.000 description 7
- JTPZTKBRUCILQD-UHFFFAOYSA-N 1-methylimidazolidin-2-one Chemical compound CN1CCNC1=O JTPZTKBRUCILQD-UHFFFAOYSA-N 0.000 description 7
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 7
- 102000004384 Histamine H3 receptors Human genes 0.000 description 7
- 108090000981 Histamine H3 receptors Proteins 0.000 description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 7
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 7
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 6
- BZJQQRCFYKSQKX-UHFFFAOYSA-N 1-(5-bromopyridin-2-yl)pyrrolidin-2-one Chemical compound N1=CC(Br)=CC=C1N1C(=O)CCC1 BZJQQRCFYKSQKX-UHFFFAOYSA-N 0.000 description 6
- JXMRRRVOKOPLCD-UHFFFAOYSA-N 1-[5-(6-benzyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)pyridin-2-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C(N2N=C3CCN(CC=4C=CC=CC=4)CCC3=C2)C=N1 JXMRRRVOKOPLCD-UHFFFAOYSA-N 0.000 description 6
- WBYWWQLHAXLGPX-UHFFFAOYSA-N 1-methyl-3-[4-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)phenyl]imidazolidin-2-one Chemical compound O=C1N(C)CCN1C1=CC=C(N2N=C3CCNCCC3=C2)C=C1 WBYWWQLHAXLGPX-UHFFFAOYSA-N 0.000 description 6
- SOAXOIPIFFFTDI-UHFFFAOYSA-N 2-(4-bromophenyl)-6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1=CC(Br)=CC=C1N1N=C2CCN(C3CCC3)CCC2=C1 SOAXOIPIFFFTDI-UHFFFAOYSA-N 0.000 description 6
- GEZKKYDMBPHUKG-UHFFFAOYSA-N 3-[4-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)phenyl]-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1C1=CC=C(N2N=C3CCNCCC3=C2)C=C1 GEZKKYDMBPHUKG-UHFFFAOYSA-N 0.000 description 6
- ZKJHVKPOOLTPHQ-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1N1N=C2CCNCCC2=C1 ZKJHVKPOOLTPHQ-UHFFFAOYSA-N 0.000 description 6
- JVLPSIRKUZEJDS-UHFFFAOYSA-N 6-benzyl-2-(4-bromophenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1=CC(Br)=CC=C1N1N=C2CCN(CC=3C=CC=CC=3)CCC2=C1 JVLPSIRKUZEJDS-UHFFFAOYSA-N 0.000 description 6
- YYZKXMYZEYHQLX-UHFFFAOYSA-N 6-cyclobutyl-4,5,7,8-tetrahydro-1h-pyrazolo[3,4-d]azepine Chemical compound C1CCC1N1CCC2=NNC=C2CC1 YYZKXMYZEYHQLX-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 239000005864 Sulphur Chemical group 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 150000003840 hydrochlorides Chemical class 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 6
- LDUGHRZZTQLJNI-UHFFFAOYSA-N n-methyl-4-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1N1N=C2CCNCCC2=C1 LDUGHRZZTQLJNI-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- GKGCQJQJBQEUNN-UHFFFAOYSA-N 3-methyl-5-[4-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)phenyl]-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2C=CC(=CC=2)N2N=C3CCNCCC3=C2)=N1 GKGCQJQJBQEUNN-UHFFFAOYSA-N 0.000 description 5
- WCFICMRMCLYOCP-UHFFFAOYSA-N 4-[6-[(2-methylpropan-2-yl)oxycarbonyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]benzoic acid Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C1=CC=C(C(O)=O)C=C1 WCFICMRMCLYOCP-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 5
- YNHBHIKWCYXZHS-UHFFFAOYSA-N n-[(1-benzyl-5-chloro-2,3,6,7-tetrahydroazepin-4-yl)methylidene]hydroxylamine Chemical compound C1CC(C=NO)=C(Cl)CCN1CC1=CC=CC=C1 YNHBHIKWCYXZHS-UHFFFAOYSA-N 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- BEUZZCQHBRKLEK-UHFFFAOYSA-N tert-butyl 2-[4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCOC1=O BEUZZCQHBRKLEK-UHFFFAOYSA-N 0.000 description 5
- LEAMRVPDQWMOLI-UHFFFAOYSA-N tert-butyl 2-[4-(3-methyl-2-oxoimidazolidin-1-yl)phenyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound O=C1N(C)CCN1C1=CC=C(N2N=C3CCN(CCC3=C2)C(=O)OC(C)(C)C)C=C1 LEAMRVPDQWMOLI-UHFFFAOYSA-N 0.000 description 5
- PCCHYOUYRRGEJP-UHFFFAOYSA-N 1-[5-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)pyridin-2-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C(N2N=C3CCN(CCC3=C2)C2CCC2)C=N1 PCCHYOUYRRGEJP-UHFFFAOYSA-N 0.000 description 4
- RRVIUDRKTCAHQZ-UHFFFAOYSA-N 1-benzylazepan-4-one Chemical compound C1CC(=O)CCCN1CC1=CC=CC=C1 RRVIUDRKTCAHQZ-UHFFFAOYSA-N 0.000 description 4
- DGBYHHMLWZHXBJ-UHFFFAOYSA-N 1-methyl-3-[4-[6-(2-methylpropyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]phenyl]imidazolidin-2-one Chemical compound N1=C2CCN(CC(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCN(C)C1=O DGBYHHMLWZHXBJ-UHFFFAOYSA-N 0.000 description 4
- GRPVZJDCANSUAN-UHFFFAOYSA-N 4-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1N1N=C2CCN(C3CCC3)CCC2=C1 GRPVZJDCANSUAN-UHFFFAOYSA-N 0.000 description 4
- FKMCNNQUQUOWGA-UHFFFAOYSA-N 4-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1N1N=C2CCN(C3CCC3)CCC2=C1 FKMCNNQUQUOWGA-UHFFFAOYSA-N 0.000 description 4
- FEGQAGVINYJWQB-UHFFFAOYSA-N 4-(6-cyclopentyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1N1N=C2CCN(C3CCCC3)CCC2=C1 FEGQAGVINYJWQB-UHFFFAOYSA-N 0.000 description 4
- AOYIAIJDZFBYFU-UHFFFAOYSA-N 4-(6-cyclopentyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1N1N=C2CCN(C3CCCC3)CCC2=C1 AOYIAIJDZFBYFU-UHFFFAOYSA-N 0.000 description 4
- LSAPKWBXLMSNAH-UHFFFAOYSA-N 6-benzyl-2-(6-bromopyridin-3-yl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1=NC(Br)=CC=C1N1N=C2CCN(CC=3C=CC=CC=3)CCC2=C1 LSAPKWBXLMSNAH-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 4
- 229960001484 edetic acid Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- UUHZTZMUMYVQKT-UHFFFAOYSA-N n,n-dimethyl-4-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1N1N=C2CCNCCC2=C1 UUHZTZMUMYVQKT-UHFFFAOYSA-N 0.000 description 4
- QQTHOWDVHYQAMT-UHFFFAOYSA-N n,n-dimethyl-4-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)benzamide Chemical compound N1=C2CCN(C(C)C)CCC2=CN1C1=CC=C(C(=O)N(C)C)C=C1 QQTHOWDVHYQAMT-UHFFFAOYSA-N 0.000 description 4
- VTAUUAREMLCUCJ-UHFFFAOYSA-N n-methyl-4-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1N1N=C2CCN(C(C)C)CCC2=C1 VTAUUAREMLCUCJ-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 4
- 229960003081 probenecid Drugs 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- NCBMLYMGSJDNIV-UHFFFAOYSA-N tert-butyl 2-(4-cyanophenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C1=CC=C(C#N)C=C1 NCBMLYMGSJDNIV-UHFFFAOYSA-N 0.000 description 4
- XNRIIQFKMOAWRP-UHFFFAOYSA-N 1,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepine;hydrochloride Chemical compound Cl.C1CNCCC2=C1NN=C2 XNRIIQFKMOAWRP-UHFFFAOYSA-N 0.000 description 3
- NHLUUDFTIYLGCR-UHFFFAOYSA-N 1-[4-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]pyrrolidin-2-one Chemical compound N1=C2CCN(C(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCCC1=O NHLUUDFTIYLGCR-UHFFFAOYSA-N 0.000 description 3
- ITTWWZOLJRGZMQ-UHFFFAOYSA-N 1-[5-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)pyridin-2-yl]pyrrolidin-2-one;hydrochloride Chemical compound Cl.N1=C2CCN(C(C)C)CCC2=CN1C(C=N1)=CC=C1N1CCCC1=O ITTWWZOLJRGZMQ-UHFFFAOYSA-N 0.000 description 3
- TVIICJDDSIMWQT-UHFFFAOYSA-N 1-benzylazepan-4-one;hydrochloride Chemical compound Cl.C1CC(=O)CCCN1CC1=CC=CC=C1 TVIICJDDSIMWQT-UHFFFAOYSA-N 0.000 description 3
- OMQDMLJDNXMHDR-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1N=C2CCNCCC2=C1 OMQDMLJDNXMHDR-UHFFFAOYSA-N 0.000 description 3
- KJEHUNZZVLFIBT-UHFFFAOYSA-N 2-(4-piperidin-1-ylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CCCCN1C1=CC=C(N2N=C3CCNCCC3=C2)C=C1 KJEHUNZZVLFIBT-UHFFFAOYSA-N 0.000 description 3
- KLOAUSDLKVHYTP-UHFFFAOYSA-N 2-(4-pyrrolidin-1-ylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CCCN1C1=CC=C(N2N=C3CCNCCC3=C2)C=C1 KLOAUSDLKVHYTP-UHFFFAOYSA-N 0.000 description 3
- VMONFDDAPIFCCI-UHFFFAOYSA-N 2-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound N1=C2CCNCCC2=CN1C1=CC=CC=C1 VMONFDDAPIFCCI-UHFFFAOYSA-N 0.000 description 3
- KQGXBEQKKDNBEF-UHFFFAOYSA-N 3-[4-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]-1,3-oxazolidin-2-one Chemical compound N1=C2CCN(C(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCOC1=O KQGXBEQKKDNBEF-UHFFFAOYSA-N 0.000 description 3
- AWDDKLXCUGGDTN-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1N1N=C2CCNCCC2=C1 AWDDKLXCUGGDTN-UHFFFAOYSA-N 0.000 description 3
- NZGTZGNHBYHCHG-UHFFFAOYSA-N 4-[(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1N=C2CCN(C3CCC3)CCC2=C1 NZGTZGNHBYHCHG-UHFFFAOYSA-N 0.000 description 3
- SCYQCPUBNNKNFU-UHFFFAOYSA-N 6-cyclobutyl-2-phenyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1CCC1N1CCC2=NN(C=3C=CC=CC=3)C=C2CC1 SCYQCPUBNNKNFU-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 3
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001502 aryl halides Chemical class 0.000 description 3
- WFTRLIZPJMFJER-UHFFFAOYSA-N azepan-1-ium-4-one;chloride Chemical compound Cl.O=C1CCCNCC1 WFTRLIZPJMFJER-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- KMPBTRDNKULAIB-UHFFFAOYSA-N n,n-dimethyl-4-[6-(2-methylpropyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]benzamide Chemical compound N1=C2CCN(CC(C)C)CCC2=CN1C1=CC=C(C(=O)N(C)C)C=C1 KMPBTRDNKULAIB-UHFFFAOYSA-N 0.000 description 3
- GUUUHLXDALJOGD-UHFFFAOYSA-N n-[4-(5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl)phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1N1N=C2CCNCCC2=C1 GUUUHLXDALJOGD-UHFFFAOYSA-N 0.000 description 3
- KMROEJOHJJYSOS-UHFFFAOYSA-N n-methyl-4-[6-(2-methylpropyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1N1N=C2CCN(CC(C)C)CCC2=C1 KMROEJOHJJYSOS-UHFFFAOYSA-N 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RYCNDXTUBKDPIG-UHFFFAOYSA-N tert-butyl 2-(1-benzylpiperidin-4-yl)-3-oxo-4,5,7,8-tetrahydro-3ah-pyrazolo[3,4-d]azepine-6-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC(C2=O)C1=NN2C(CC1)CCN1CC1=CC=CC=C1 RYCNDXTUBKDPIG-UHFFFAOYSA-N 0.000 description 3
- NIDDPAKUFCXULA-UHFFFAOYSA-N tert-butyl 2-(4-carbamoylphenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C1=CC=C(C(N)=O)C=C1 NIDDPAKUFCXULA-UHFFFAOYSA-N 0.000 description 3
- AIJQOCXEQSILSY-UHFFFAOYSA-N tert-butyl 2-(4-methylsulfonylphenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C1=CC=C(S(C)(=O)=O)C=C1 AIJQOCXEQSILSY-UHFFFAOYSA-N 0.000 description 3
- GKICBDGWUCGOSW-UHFFFAOYSA-N tert-butyl 2-(4-piperidin-1-ylphenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCCCC1 GKICBDGWUCGOSW-UHFFFAOYSA-N 0.000 description 3
- SGLXWPUWKJWXRB-UHFFFAOYSA-N tert-butyl 2-(4-pyrrolidin-1-ylphenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCCC1 SGLXWPUWKJWXRB-UHFFFAOYSA-N 0.000 description 3
- KVNAWBPGYXBQSB-UHFFFAOYSA-N tert-butyl 2-(6-bromopyridin-3-yl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C1=CC=C(Br)N=C1 KVNAWBPGYXBQSB-UHFFFAOYSA-N 0.000 description 3
- JJKROYJLOXTEHU-UHFFFAOYSA-N tert-butyl 2-[1-(6-methylpyridin-3-yl)piperidin-4-yl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound C1=NC(C)=CC=C1N1CCC(N2N=C3CCN(CCC3=C2)C(=O)OC(C)(C)C)CC1 JJKROYJLOXTEHU-UHFFFAOYSA-N 0.000 description 3
- HCHKLSXPSGLFJO-UHFFFAOYSA-N tert-butyl 2-[4-(2-oxopyrrolidin-1-yl)phenyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCCC1=O HCHKLSXPSGLFJO-UHFFFAOYSA-N 0.000 description 3
- BCVQCOKWKNGTLM-UHFFFAOYSA-N tert-butyl 2-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound CC1=NOC(C=2C=CC(=CC=2)N2N=C3CCN(CCC3=C2)C(=O)OC(C)(C)C)=N1 BCVQCOKWKNGTLM-UHFFFAOYSA-N 0.000 description 3
- RMZOWVHIMLGLBC-UHFFFAOYSA-N tert-butyl 2-[4-(dimethylcarbamoyl)phenyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound C1=CC(C(=O)N(C)C)=CC=C1N1N=C2CCN(C(=O)OC(C)(C)C)CCC2=C1 RMZOWVHIMLGLBC-UHFFFAOYSA-N 0.000 description 3
- SMIGUQBCGWRCHP-UHFFFAOYSA-N tert-butyl 2-[4-(methanesulfonamido)phenyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C1=CC=C(NS(C)(=O)=O)C=C1 SMIGUQBCGWRCHP-UHFFFAOYSA-N 0.000 description 3
- TWYFTHGQLCSIID-UHFFFAOYSA-N tert-butyl 2-[4-(methylcarbamoyl)phenyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound C1=CC(C(=O)NC)=CC=C1N1N=C2CCN(C(=O)OC(C)(C)C)CCC2=C1 TWYFTHGQLCSIID-UHFFFAOYSA-N 0.000 description 3
- UUVQQVIKZUMWAB-UHFFFAOYSA-N tert-butyl 2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C(C=N1)=CC=C1N1CCCC1=O UUVQQVIKZUMWAB-UHFFFAOYSA-N 0.000 description 3
- DAZPEMJSUKJYBU-UHFFFAOYSA-N tert-butyl 2-piperidin-4-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound N1=C2CCN(C(=O)OC(C)(C)C)CCC2=CN1C1CCNCC1 DAZPEMJSUKJYBU-UHFFFAOYSA-N 0.000 description 3
- PDXQWQKJVPRLMF-UHFFFAOYSA-N tert-butyl 4-formyl-5-oxoazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)C(=O)CC1 PDXQWQKJVPRLMF-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 2
- BCYWDUVHAPHGIP-UHFFFAOYSA-N (6-bromopyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=C(Br)N=C1 BCYWDUVHAPHGIP-UHFFFAOYSA-N 0.000 description 2
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 2
- ZHUMMBWCLVAHDW-UHFFFAOYSA-N 1-(4-bromophenyl)-6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1=CC(Br)=CC=C1N1C(CCN(CC2)C3CCC3)=C2C=N1 ZHUMMBWCLVAHDW-UHFFFAOYSA-N 0.000 description 2
- YINFEFUSAQRZGG-UHFFFAOYSA-N 1-(4-bromophenyl)pyrrolidin-2-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)CCC1 YINFEFUSAQRZGG-UHFFFAOYSA-N 0.000 description 2
- XUXLXFNWTHSVDU-UHFFFAOYSA-N 1-[4-(6-cyclohexyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C(N2N=C3CCN(CCC3=C2)C2CCCCC2)C=C1 XUXLXFNWTHSVDU-UHFFFAOYSA-N 0.000 description 2
- NUCUHFOXKYAJSO-UHFFFAOYSA-N 1-[4-(6-cyclopentyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]-3-methylimidazolidin-2-one Chemical compound O=C1N(C)CCN1C1=CC=C(N2N=C3CCN(CCC3=C2)C2CCCC2)C=C1 NUCUHFOXKYAJSO-UHFFFAOYSA-N 0.000 description 2
- PFKVVKZVZKQJIY-UHFFFAOYSA-N 1-[4-(6-cyclopentyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C(N2N=C3CCN(CCC3=C2)C2CCCC2)C=C1 PFKVVKZVZKQJIY-UHFFFAOYSA-N 0.000 description 2
- UNFFLKKHVRORSL-UHFFFAOYSA-N 1-[4-(6-ethyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]pyrrolidin-2-one Chemical compound N1=C2CCN(CC)CCC2=CN1C(C=C1)=CC=C1N1CCCC1=O UNFFLKKHVRORSL-UHFFFAOYSA-N 0.000 description 2
- QZEZLNQKBWZPDJ-UHFFFAOYSA-N 1-[4-[6-(2-methylpropyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]phenyl]pyrrolidin-2-one Chemical compound N1=C2CCN(CC(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCCC1=O QZEZLNQKBWZPDJ-UHFFFAOYSA-N 0.000 description 2
- FBLPODTYWKUWKU-UHFFFAOYSA-N 1-[4-[6-(cyclopropylmethyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]phenyl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C(N2N=C3CCN(CC4CC4)CCC3=C2)C=C1 FBLPODTYWKUWKU-UHFFFAOYSA-N 0.000 description 2
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 2
- MGKKZYOFKNDJGD-UHFFFAOYSA-N 3-[4-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]-1-methylimidazolidine-2,4-dione Chemical compound O=C1N(C)CC(=O)N1C1=CC=C(N2N=C3CCN(CCC3=C2)C2CCC2)C=C1 MGKKZYOFKNDJGD-UHFFFAOYSA-N 0.000 description 2
- XEZCPAVXKBUPRY-UHFFFAOYSA-N 3-[4-(6-cyclopentyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1C1=CC=C(N2N=C3CCN(CCC3=C2)C2CCCC2)C=C1 XEZCPAVXKBUPRY-UHFFFAOYSA-N 0.000 description 2
- ULDBTTCHMFJGSK-UHFFFAOYSA-N 3-[4-[6-(2-methylpropyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]phenyl]-1,3-oxazolidin-2-one Chemical compound N1=C2CCN(CC(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCOC1=O ULDBTTCHMFJGSK-UHFFFAOYSA-N 0.000 description 2
- FBCIOSJGCBSUPO-UHFFFAOYSA-N 3-methyl-5-[4-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]-1,2,4-oxadiazole Chemical compound N1=C2CCN(C(C)C)CCC2=CN1C(C=C1)=CC=C1C1=NC(C)=NO1 FBCIOSJGCBSUPO-UHFFFAOYSA-N 0.000 description 2
- OSKJMVLSHZZCLF-UHFFFAOYSA-N 3-methyl-5-[4-[6-(2-methylpropyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]phenyl]-1,2,4-oxadiazole Chemical compound N1=C2CCN(CC(C)C)CCC2=CN1C(C=C1)=CC=C1C1=NC(C)=NO1 OSKJMVLSHZZCLF-UHFFFAOYSA-N 0.000 description 2
- JSPMYAZGTGJOAI-UHFFFAOYSA-N 4-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1N1N=C2CCN(C3CCC3)CCC2=C1 JSPMYAZGTGJOAI-UHFFFAOYSA-N 0.000 description 2
- YLZHGJSNBVVMHA-UHFFFAOYSA-N 4-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1N1N=C2CCN(C3CCC3)CCC2=C1 YLZHGJSNBVVMHA-UHFFFAOYSA-N 0.000 description 2
- NXNUSIGCWNWZFT-UHFFFAOYSA-N 4-(6-cyclopentyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1N1N=C2CCN(C3CCCC3)CCC2=C1 NXNUSIGCWNWZFT-UHFFFAOYSA-N 0.000 description 2
- ULJXVGFBRBQVFN-UHFFFAOYSA-N 4-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)benzamide Chemical compound N1=C2CCN(C(C)C)CCC2=CN1C1=CC=C(C(N)=O)C=C1 ULJXVGFBRBQVFN-UHFFFAOYSA-N 0.000 description 2
- YBIUXOJYXHYIKE-UHFFFAOYSA-N 4-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)benzonitrile Chemical compound N1=C2CCN(C(C)C)CCC2=CN1C1=CC=C(C#N)C=C1 YBIUXOJYXHYIKE-UHFFFAOYSA-N 0.000 description 2
- XSZLCHNKJCBKCB-UHFFFAOYSA-N 4-[4-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]morpholine Chemical compound C1CCC1N1CCC2=NN(C=3C=CC(=CC=3)N3CCOCC3)C=C2CC1 XSZLCHNKJCBKCB-UHFFFAOYSA-N 0.000 description 2
- WRTSWARSQLNKPU-UHFFFAOYSA-N 4-[6-(2-methylpropyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]benzamide Chemical compound N1=C2CCN(CC(C)C)CCC2=CN1C1=CC=C(C(N)=O)C=C1 WRTSWARSQLNKPU-UHFFFAOYSA-N 0.000 description 2
- DDAFYRLZURWYBU-UHFFFAOYSA-N 4-[6-(2-methylpropyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl]benzonitrile Chemical compound N1=C2CCN(CC(C)C)CCC2=CN1C1=CC=C(C#N)C=C1 DDAFYRLZURWYBU-UHFFFAOYSA-N 0.000 description 2
- ZZWYBGWBUVCGCI-UHFFFAOYSA-N 5-[4-(6-cyclopentyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2C=CC(=CC=2)N2N=C3CCN(CCC3=C2)C2CCCC2)=N1 ZZWYBGWBUVCGCI-UHFFFAOYSA-N 0.000 description 2
- PEAOEIWYQVXZMB-UHFFFAOYSA-N 5-bromo-2-chloropyridine Chemical compound ClC1=CC=C(Br)C=N1 PEAOEIWYQVXZMB-UHFFFAOYSA-N 0.000 description 2
- OFKWIQJLYCKDNY-UHFFFAOYSA-N 5-bromo-2-methylpyridine Chemical compound CC1=CC=C(Br)C=N1 OFKWIQJLYCKDNY-UHFFFAOYSA-N 0.000 description 2
- BYXQPVYYCODYFR-UHFFFAOYSA-N 6-cyclobutyl-2-(4-methylsulfonylphenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1N=C2CCN(C3CCC3)CCC2=C1 BYXQPVYYCODYFR-UHFFFAOYSA-N 0.000 description 2
- IRXCERGGZYNFJI-UHFFFAOYSA-N 6-cyclobutyl-2-(4-piperidin-1-ylphenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1CCC1N1CCC2=NN(C=3C=CC(=CC=3)N3CCCCC3)C=C2CC1 IRXCERGGZYNFJI-UHFFFAOYSA-N 0.000 description 2
- RUGQPDGXAJMLNQ-UHFFFAOYSA-N 6-cyclobutyl-2-(4-pyrrolidin-1-ylphenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1CCC1N1CCC2=NN(C=3C=CC(=CC=3)N3CCCC3)C=C2CC1 RUGQPDGXAJMLNQ-UHFFFAOYSA-N 0.000 description 2
- IUMZUJYPSCQKNK-UHFFFAOYSA-N 6-cyclobutyl-2-[1-(6-methylpyridin-3-yl)piperidin-4-yl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1=NC(C)=CC=C1N1CCC(N2N=C3CCN(CCC3=C2)C2CCC2)CC1 IUMZUJYPSCQKNK-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- RHYBFKMFHLPQPH-UHFFFAOYSA-N N-methylhydantoin Chemical compound CN1CC(=O)NC1=O RHYBFKMFHLPQPH-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 125000005620 boronic acid group Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 125000005959 diazepanyl group Chemical group 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- CIPMKIHUGVGQTG-VFFZMTJFSA-N leupeptin hemisulfate Chemical compound OS(O)(=O)=O.CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N.CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N CIPMKIHUGVGQTG-VFFZMTJFSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ZZCHUBZBYAFNPJ-UHFFFAOYSA-N (1-benzylpiperidin-4-yl)hydrazine;dihydrochloride Chemical compound Cl.Cl.C1CC(NN)CCN1CC1=CC=CC=C1 ZZCHUBZBYAFNPJ-UHFFFAOYSA-N 0.000 description 1
- PLVCYMZAEQRYHJ-UHFFFAOYSA-N (2-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Br PLVCYMZAEQRYHJ-UHFFFAOYSA-N 0.000 description 1
- CEBAHYWORUOILU-UHFFFAOYSA-N (4-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=C(C#N)C=C1 CEBAHYWORUOILU-UHFFFAOYSA-N 0.000 description 1
- VDUKDQTYMWUSAC-UHFFFAOYSA-N (4-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=C(B(O)O)C=C1 VDUKDQTYMWUSAC-UHFFFAOYSA-N 0.000 description 1
- QIQWRCNAPQJQLL-COALEZEGSA-N (z)-but-2-enedioic acid;5-[(1r,2r)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1h-imidazole Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)CCC#C[C@@H]1C[C@H]1C1=CN=CN1 QIQWRCNAPQJQLL-COALEZEGSA-N 0.000 description 1
- XVYPKEBYTBRBEC-UHFFFAOYSA-N 1,2,3,3a,4,5-hexahydropyrazolo[3,4-d]azepine Chemical compound C1=NCCC2CNNC2=C1 XVYPKEBYTBRBEC-UHFFFAOYSA-N 0.000 description 1
- DTFNQANOSNEOCD-UHFFFAOYSA-N 1-[4-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]-3-methylimidazolidin-2-one Chemical compound O=C1N(C)CCN1C1=CC=C(N2N=C3CCN(CCC3=C2)C2CCC2)C=C1 DTFNQANOSNEOCD-UHFFFAOYSA-N 0.000 description 1
- SWGKYHKUYIKLDC-UHFFFAOYSA-N 1-[4-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C(N2N=C3CCN(CCC3=C2)C2CCC2)C=C1 SWGKYHKUYIKLDC-UHFFFAOYSA-N 0.000 description 1
- UTZALURJTZPLMS-UHFFFAOYSA-N 1-[5-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)pyridin-2-yl]pyrrolidin-2-one Chemical compound N1=C2CCN(C(C)C)CCC2=CN1C(C=N1)=CC=C1N1CCCC1=O UTZALURJTZPLMS-UHFFFAOYSA-N 0.000 description 1
- BKADWIISZKEYEA-UHFFFAOYSA-N 1-methyl-3-[4-(6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]imidazolidin-2-one Chemical compound N1=C2CCN(C(C)C)CCC2=CN1C(C=C1)=CC=C1N1CCN(C)C1=O BKADWIISZKEYEA-UHFFFAOYSA-N 0.000 description 1
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MWVMYAWMFTVYED-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC=CC=C21 MWVMYAWMFTVYED-UHFFFAOYSA-N 0.000 description 1
- HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229940124801 5-HT6 antagonist Drugs 0.000 description 1
- PPKYYYZMDGNSDA-UHFFFAOYSA-N 5-[4-(6-cyclobutyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-2-yl)phenyl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(C=2C=CC(=CC=2)N2N=C3CCN(CCC3=C2)C2CCC2)=N1 PPKYYYZMDGNSDA-UHFFFAOYSA-N 0.000 description 1
- LHHSJRJGCQXOIP-UHFFFAOYSA-N 7-benzyl-4,5,6,8-tetrahydro-1h-pyrazolo[3,4-c]azepine Chemical compound C1CCC2=CNN=C2CN1CC1=CC=CC=C1 LHHSJRJGCQXOIP-UHFFFAOYSA-N 0.000 description 1
- CLMPYYWTFMYDKT-UHFFFAOYSA-N 7-cyclobutyl-2-phenyl-4,5,6,8-tetrahydropyrazolo[3,4-c]azepine Chemical compound C1CCC1N1CC2=NN(C=3C=CC=CC=3)C=C2CCC1 CLMPYYWTFMYDKT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241001032544 Galearctus aurora Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150111468 H3 gene Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920001367 Merrifield resin Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UXRDAJMOOGEIAQ-CKOZHMEPSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-10,13-dimethyl-16-methylidene-3-oxo-1,2,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UXRDAJMOOGEIAQ-CKOZHMEPSA-N 0.000 description 1
- NDVJJEADFLTFCD-UHFFFAOYSA-N [4-(methanesulfonamido)phenyl]boronic acid Chemical compound CS(=O)(=O)NC1=CC=C(B(O)O)C=C1 NDVJJEADFLTFCD-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 150000008038 benzoazepines Chemical class 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 101150038738 ble gene Proteins 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- ACQBHJXEAYTHCY-UHFFFAOYSA-N cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone Chemical compound C=1C=C(OCCCC=2NC=NC=2)C=CC=1C(=O)C1CC1 ACQBHJXEAYTHCY-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000007345 electrophilic aromatic substitution reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000010641 nitrile hydrolysis reaction Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- PMLBUVZPRKXMOX-UHFFFAOYSA-N tert-butyl 4-oxoazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(=O)CC1 PMLBUVZPRKXMOX-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0513886.2 | 2005-07-06 | ||
| GBGB0513886.2A GB0513886D0 (en) | 2005-07-06 | 2005-07-06 | Novel compounds |
| PCT/EP2006/006613 WO2007025596A1 (en) | 2005-07-06 | 2006-07-04 | Pyrazolo [3 , 4-d] azepine derivatives as histamine h3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2614232A1 true CA2614232A1 (en) | 2007-03-08 |
Family
ID=34856781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002614232A Abandoned CA2614232A1 (en) | 2005-07-06 | 2006-07-04 | Pyrazolo [3,4-d] azepine derivatives as histamine h3 antagonists |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7888347B2 (https=) |
| EP (1) | EP1899350B1 (https=) |
| JP (1) | JP5145218B2 (https=) |
| KR (1) | KR20080037651A (https=) |
| CN (1) | CN101258154B (https=) |
| AT (1) | ATE467636T1 (https=) |
| AU (1) | AU2006286897A1 (https=) |
| BR (1) | BRPI0612719A2 (https=) |
| CA (1) | CA2614232A1 (https=) |
| CR (1) | CR9622A (https=) |
| CY (1) | CY1110711T1 (https=) |
| DE (1) | DE602006014273D1 (https=) |
| DK (1) | DK1899350T3 (https=) |
| EA (1) | EA013600B1 (https=) |
| ES (1) | ES2345841T3 (https=) |
| GB (1) | GB0513886D0 (https=) |
| HR (1) | HRP20100401T1 (https=) |
| IL (1) | IL188184A0 (https=) |
| MA (1) | MA29623B1 (https=) |
| MX (1) | MX2008000383A (https=) |
| NO (1) | NO20080563L (https=) |
| PL (1) | PL1899350T3 (https=) |
| PT (1) | PT1899350E (https=) |
| SI (1) | SI1899350T1 (https=) |
| UA (1) | UA93047C2 (https=) |
| WO (1) | WO2007025596A1 (https=) |
| ZA (1) | ZA200710798B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103382174A (zh) | 2006-06-23 | 2013-11-06 | 雅培制药有限公司 | 作为组胺h3受体调节物的环丙胺衍生物 |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| KR20100059919A (ko) | 2007-09-24 | 2010-06-04 | 코멘티스, 인코포레이티드 | 치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물 |
| US9186353B2 (en) * | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| CN102952139B (zh) * | 2011-08-30 | 2016-08-10 | 上海药明康德新药开发有限公司 | 反式-3a-氟吡咯烷[3,4-C]并环化合物及其制备方法 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| US9910887B2 (en) * | 2013-04-25 | 2018-03-06 | Facebook, Inc. | Variable search query vertical access |
| MX2018014034A (es) * | 2016-05-25 | 2019-08-29 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6018799A (en) * | 1998-09-09 | 2000-03-27 | Ishihara Sangyo Kaisha Ltd. | Fused-benzene derivatives useful as herbicides |
| JP2002542245A (ja) * | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 置換イミダゾール、それらの製造および使用 |
| JP2001220390A (ja) | 2000-02-09 | 2001-08-14 | Yamanouchi Pharmaceut Co Ltd | 縮合ピラゾール誘導体 |
| ES2283768T3 (es) * | 2002-06-06 | 2007-11-01 | Novo Nordisk A/S | Hexahidropirrolo(1,2-a)piracinas, octahidropirido(1,2-a)piracinas y decahidropiracino(1,2-a)acepinas sustituidas. |
| US6770597B2 (en) | 2002-07-17 | 2004-08-03 | Ishihara Sangyo Kaisha, Ltd. | Benzohydrazide derivatives as herbicides and desiccant compositions containing them |
| JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
| EP1539704A1 (en) * | 2002-08-20 | 2005-06-15 | Eli Lilly And Company | Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses |
| GB0224083D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP2133340B1 (en) | 2002-12-20 | 2013-01-16 | Glaxo Group Limited | Novel benzazepine derivatives |
| SI1668014T1 (sl) * | 2003-09-17 | 2009-06-30 | Janssen Pharmaceutica Nv | Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev |
| GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| GB0405628D0 (en) | 2004-03-12 | 2004-04-21 | Glaxo Group Ltd | Novel compounds |
| GB0408083D0 (en) | 2004-04-08 | 2004-05-12 | Glaxo Group Ltd | Novel compounds |
| WO2005123723A1 (en) | 2004-06-18 | 2005-12-29 | Glaxo Group Limited | 3-cycloalkylbenzazepines as histamine h3 antagonists |
| GB0418267D0 (en) | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
| RU2007125648A (ru) | 2004-12-07 | 2009-01-20 | Глэксо Груп Лимитед (GB) | Инденильные производные и их применение для лечения неврологических расстройств |
| US20080161289A1 (en) | 2005-03-14 | 2008-07-03 | Glaxo Group Limited | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor |
-
2005
- 2005-07-06 GB GBGB0513886.2A patent/GB0513886D0/en not_active Ceased
-
2006
- 2006-07-04 JP JP2008519862A patent/JP5145218B2/ja not_active Expired - Fee Related
- 2006-07-04 HR HR20100401T patent/HRP20100401T1/hr unknown
- 2006-07-04 AU AU2006286897A patent/AU2006286897A1/en not_active Abandoned
- 2006-07-04 AT AT06818218T patent/ATE467636T1/de active
- 2006-07-04 BR BRPI0612719-3A patent/BRPI0612719A2/pt not_active IP Right Cessation
- 2006-07-04 ES ES06818218T patent/ES2345841T3/es active Active
- 2006-07-04 PL PL06818218T patent/PL1899350T3/pl unknown
- 2006-07-04 EP EP06818218A patent/EP1899350B1/en not_active Not-in-force
- 2006-07-04 US US11/994,689 patent/US7888347B2/en not_active Expired - Fee Related
- 2006-07-04 MX MX2008000383A patent/MX2008000383A/es active IP Right Grant
- 2006-07-04 UA UAA200800190A patent/UA93047C2/ru unknown
- 2006-07-04 CN CN2006800322776A patent/CN101258154B/zh not_active Expired - Fee Related
- 2006-07-04 EA EA200800264A patent/EA013600B1/ru not_active IP Right Cessation
- 2006-07-04 WO PCT/EP2006/006613 patent/WO2007025596A1/en not_active Ceased
- 2006-07-04 DE DE602006014273T patent/DE602006014273D1/de active Active
- 2006-07-04 CA CA002614232A patent/CA2614232A1/en not_active Abandoned
- 2006-07-04 SI SI200630733T patent/SI1899350T1/sl unknown
- 2006-07-04 KR KR1020087000265A patent/KR20080037651A/ko not_active Ceased
- 2006-07-04 PT PT06818218T patent/PT1899350E/pt unknown
- 2006-07-04 DK DK06818218.7T patent/DK1899350T3/da active
-
2007
- 2007-12-12 ZA ZA200710798A patent/ZA200710798B/xx unknown
- 2007-12-17 IL IL188184A patent/IL188184A0/en unknown
- 2007-12-20 CR CR9622A patent/CR9622A/es not_active Application Discontinuation
-
2008
- 2008-01-09 MA MA30562A patent/MA29623B1/fr unknown
- 2008-01-30 NO NO20080563A patent/NO20080563L/no not_active Application Discontinuation
-
2010
- 2010-07-29 CY CY20101100713T patent/CY1110711T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2345841T3 (es) | 2010-10-04 |
| CN101258154A (zh) | 2008-09-03 |
| JP2009500366A (ja) | 2009-01-08 |
| WO2007025596A1 (en) | 2007-03-08 |
| EA200800264A1 (ru) | 2008-06-30 |
| SI1899350T1 (sl) | 2010-09-30 |
| MX2008000383A (es) | 2008-03-07 |
| CY1110711T1 (el) | 2015-06-10 |
| JP5145218B2 (ja) | 2013-02-13 |
| NO20080563L (no) | 2008-02-01 |
| EA013600B1 (ru) | 2010-06-30 |
| US7888347B2 (en) | 2011-02-15 |
| DE602006014273D1 (de) | 2010-06-24 |
| CN101258154B (zh) | 2011-01-19 |
| CR9622A (es) | 2008-04-10 |
| HRP20100401T1 (hr) | 2010-09-30 |
| IL188184A0 (en) | 2008-03-20 |
| UA93047C2 (ru) | 2011-01-10 |
| ATE467636T1 (de) | 2010-05-15 |
| DK1899350T3 (da) | 2010-09-06 |
| GB0513886D0 (en) | 2005-08-10 |
| EP1899350A1 (en) | 2008-03-19 |
| PL1899350T3 (pl) | 2010-10-29 |
| PT1899350E (pt) | 2010-07-21 |
| EP1899350B1 (en) | 2010-05-12 |
| MA29623B1 (fr) | 2008-07-01 |
| AU2006286897A1 (en) | 2007-03-08 |
| ZA200710798B (en) | 2008-11-26 |
| KR20080037651A (ko) | 2008-04-30 |
| US20080176832A1 (en) | 2008-07-24 |
| BRPI0612719A2 (pt) | 2010-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1802307B1 (en) | Pyrrolidine derivatives as histamine receptors ligands | |
| EP1675838A1 (en) | 1-benzoyl substituted diazepine derivatives as selective histamine h3 receptor agonists | |
| KR20050121268A (ko) | 피페라진 유도체 및 신경적 및 정신적 질병의 치료를 위한그의 용도 | |
| US7638631B2 (en) | Methylene dipiperidine derivatives | |
| US20070208005A1 (en) | Tetrahydrobenzazepines as antagonists and/or reverse agonists of the histamine h3 receptor | |
| CA2614232A1 (en) | Pyrazolo [3,4-d] azepine derivatives as histamine h3 antagonists | |
| WO2005123723A1 (en) | 3-cycloalkylbenzazepines as histamine h3 antagonists | |
| EP1858900B1 (en) | Fused thiazole derivatives having affinity for the histamine h3 receptor | |
| CA2589831A1 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
| CN101171256A (zh) | 具有组胺h3受体亲和性的稠合噻唑衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140221 |